Inventor · disambiguated record
Gideon Gross
Also filed as: GROSS GIDEON
6 granted patents·16 pending applications·1,369 citations·filing 1993–2024
89Inventor score
Files withGAVISH GALILEE BIO APPL LTD8MIGAL GALILEE RES INSTITUTE LTD5ESHHAR ZELIG3IMMPACT BIO LTD3YEDA RES & DEV2
Top patents by PatentIndex Score
22 records- 0196US7741465B1Chimeric receptor genes and cells transformed therewithESHHAR ZELIG·Filed 1993·Granted Jun 22, 2010·598 cites·20 claims
- 0296US5906936AEndowing lymphocytes with antibody specificityYEDA RES & DEV·Filed 1993·Granted May 25, 1999·271 cites·33 claims
- 0395US8211422B2Chimeric receptor genes and cells transformed therewithESHHAR ZELIG·Filed 1995·Granted Jul 3, 2012·240 cites·30 claims
- 0495US5912172AEndowing lymphocytes with antibody specificityYEDA RES & DEV·Filed 1995·Granted Jun 15, 1999·181 cites·41 claims
- 0592US7319143B2Genetically-engineered MHC moleculesGAVISH GALILEE BIO APPL LTD·Filed 2001·Granted Jan 15, 2008·79 cites·16 claims
- 0676US2024139238A1Universal platform for car therapy targeting a novel antigenic signature of cancerGAVISH GALILEE BIO APPL LTD·Filed 2024·Application pending·0 cites
- 0774US2022380434A1Universal platform for car therapy targeting a novel antigenic signature of cancerMIGAL GALILEE RES INSTITUTE LTD·Filed 2022·Application pending·0 cites
- 0870US2021230251A1Universal platform for car therapy targeting a novel antigenic signature of cancerGAVISH GALILEE BIO APPL LTD·Filed 2021·Application pending·0 cites
- 0961US11660315B2Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)IMMPACT BIO LTD·Filed 2018·Granted May 30, 2023·0 cites·11 claims
- 1061US2019248869A1A universal platform for car therapy targeting a novel antigenic signature of cancerGAVISH GALILEE BIO APPL LTD·Filed 2017·Application pending·0 cites
- 1158US2021244759A1Universal platform for car therapy targeting a novel antigenic signature of cancerIMMPACT BIO LTD·Filed 2021·Application pending·0 cites
- 1255US2023265190A1Alloreactive immune cell-distancing device and uses thereof for protecting donor-derived cells from allorejectionMIGAL GALILEE RES INSTITUTE LTD·Filed 2021·Application pending·0 cites
- 1354US2022306723A1Chimeric antigen receptor comprising cd40 cytoplasmic domain and uses thereofMIGAL GALILEE RES INSTITUTE LTD·Filed 2020·Application pending·0 cites
- 1451US2023030702A1Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cellsMIGAL GALILEE RES INSTITUTE LTD·Filed 2020·Application pending·0 cites
- 1550US2022186232A1Genetically reprogrammed tregs expressing carsGAVISH GALILEE BIO APPL LTD·Filed 2020·Application pending·0 cites
- 1649US2006003315A1Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopesGAVISH GALILEE BIO APPL LTD·Filed 2003·Application pending·0 cites
- 1749US2012093842A1Chimeric receptor genes and cells transformed therewithESHHAR ZELIG·Filed 2011·Application pending·0 cites
- 1846US2004110922A1Chimeric proteins for prevention and treatment of hiv infectionFiled 2002·Application pending·0 cites
- 1946US2021347843A9Genetically reprogrammed tregs expressing membrane-bound il-10GAVISH GALILEE BIO APPL LTD·Filed 2019·Application pending·0 cites
- 2046US2020316120A1METHODS FOR IDENTIFYING ACTIVATING ANTIGEN RECEPTOR (aCAR)/INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR) PAIRS FOR USE IN CANCER THERAPIESIMMPACT BIO LTD·Filed 2019·Application pending·0 cites
- 2145US2022348953A1SYSTEMS AND USES THEREOF FOR CREATING SYNTHETIC TRANSCRIPTIONAL LOGIC 'AND' GATES BASED ON PRE-mRNA TRANS-SPLICINGMIGAL GALILEE RES INSTITUTE LTD·Filed 2020·Application pending·0 cites
- 2243US2008286312A1Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopesGAVISH GALILEE BIO APPL LTD·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gideon Gross files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →